Charles N Serhan

List of Publications by Year
in descending order

565	85,926	143 157	451 273
papers	citations	h-index	g-index

587	587	587	39299
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews Immunology, 2008, 8, 349-361.	10.6	2,492
2	Pro-resolving lipid mediators are leads for resolution physiology. Nature, 2014, 510, 92-101.	13.7	2,266
3	Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science, 1987, 237, 1171-1176.	6.0	2,185
4	Resolution of inflammation: the beginning programs the end. Nature Immunology, 2005, 6, 1191-1197.	7.0	2,060
5	Resolvins. Journal of Experimental Medicine, 2002, 196, 1025-1037.	4.2	1,486
6	Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunology, 2001, 2, 612-619.	7.0	1,229
7	Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2â€“Nonsteroidal Antiinflammatory Drugs and Transcellular Processing. Journal of Experimental Medicine, 2000, 192, 1197-1204.	4.2	1,048
8	Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 2007, 447, 869-874.	13.7	1,046
9	Resolution of in flammation: state of the art, definitions and terms. FASEB Journal, 2007, 21, 325-332.	0.2	949
10	Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annual Review of Immunology, 2007, 25, 101-137.	9.5	910
11	Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells. Journal of Biological Chemistry, 2003, 278, 14677-14687.	1.6	872
12	Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation, 2018, 128, 2657-2669.	3.9	858
13	Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. Journal of Experimental Medicine, 2005, 201, 713-722.	4.2	829
14	Resolvins and Protectins in Inflammation Resolution. Chemical Reviews, 2011, 111, 5922-5943.	23.0	823
15	Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. Journal of Experimental Medicine, 2009, 206, 15-23.	4.2	746
16	A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Journal of Clinical Investigation, 2005, 115, 2774-2783.	3.9	740
17	Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression. Journal of Biological Chemistry, 2003, 278, 43807-43817.	1.6	714
18	From The Cover: Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8491-8496.	3.3	701

#	Article	IF	Citations
19	Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9475-9479.	3.3	682
20	International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family. Pharmacological Reviews, 2009, 61, 119-161.	7.1	677
21	Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 5335-5339.	3.3	667
22	Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. Immunity, 2014, 40, 315-327.	6.6	666
23	Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins. Journal of Immunology, 2005, 174, 4345-4355.	0.4	663
24	Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1660-1665.	3.3	638
25	Increased dietary intake of Ï‰-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medicine, 2007, 13, 868-873.	15.2	633
26	Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature, 2009, 461, 1287-1291.	13.7	599
27	Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature, 2012, 484, 524-528.	13.7	562
28	Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation. Journal of Immunology, 2007, 178, 3912-3917.	0.4	548
29	Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7671-7676.	3.3	544
30	Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections. Cell, 2012, 148, 434-446.	13.5	523
31	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	2.7	519
32	Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nature Medicine, 2010, 16, 592-597.	15.2	503
33	Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain. Neuron, 2018, 100, 1292-1311.	3.8	496
34	The resolution of inflammation. Nature Reviews Immunology, 2013, 13, 59-66.	10.6	454
35	Resolvin D1 and Its Aspirin-triggered 17R Epimer. Journal of Biological Chemistry, 2007, 282, 9323-9334.	1.6	452
36	The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Seminars in Immunology, 2015, 27, 200-215.	2.7	443

#	Article	IF	Citations
37	Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood, 2012, 120, e60-e72.	0.6	441
38	Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB Journal, 2017, 31, 1273-1288.	0.2	437
39	Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nature Medicine, 2002, 8, 1296-1302.	15.2	435
40	The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo. Pharmacological Reviews, 2006, 58, 463-487.	7.1	431
41	Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.. Journal of Experimental Medicine, 1994, 180, 253-260.	4.2	425
42	Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes. Journal of Immunology, 2006, 176, 1848-1859.	0.4	424
43	Anti-Inflammatory and Proresolving Lipid Mediators. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 279-312.	9.6	422
44	Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases. Journal of Dental Research, 2003, 82, 82-90.	2.5	413
45	Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors. Journal of Experimental Medicine, 1997, 185, 1693-1704.	4.2	405
46	Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB Journal, 2012, 26, 1755-1765.	0.2	401
47	Lipid mediator networks in cell signaling: update and impact of cytokines ¹. FASEB Journal, 1996, 10, 1147-1158.	0.2	396
48	Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo. Journal of Immunology, 2007, 179, 7021-7029.	0.4	392
49	Lipid Mediators in the Resolution of Inflammation. Cold Spring Harbor Perspectives in Biology, 2015, 7, a016311.	2.3	389
50	Resolvin E1 regulates interleukin 23, interferon-Î³ and lipoxin A4 to promote the resolution of allergic airway inflammation. Nature Immunology, 2008, 9, 873-879.	7.0	384
51	Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 141-162.	1.0	382
52	Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB Journal, 2008, 22, 3595-3606.	0.2	378
53	Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases. Cell Metabolism, 2014, 19, 21-36.	7.2	378
54	RvE1 protects from local inflammation and osteoclastmediated bone destruction in periodontitis. FASEB Journal, 2006, 20, 401-403.	0.2	374

#	Article	IF	Citations
55	Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation. American Journal of Pathology, 2010, 177, 1576-1591.	1.9	372
56	Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. American Journal of Physiology - Cell Physiology, 2014, 307, C39-C54.	2.1	370
57	Reduced Inflammation and Tissue Damage in Transgenic Rabbits Overexpressing 15-Lipoxygenase and Endogenous Anti-inflammatory Lipid Mediators. Journal of Immunology, 2003, 171, 6856-6865.	0.4	364
58	Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11276-11281.	3.3	361
59	Endogenous proâ€resolving and antiâ€inflammatory lipid mediators: a new pharmacologic genus. British Journal of Pharmacology, 2008, 153, S200-15.	2.7	360
60	Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 1260-1273.	1.2	360
61	Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 397-413.	1.2	360
62	Resolvins and protectins in the termination program of acute inflammation. Trends in Immunology, 2007, 28, 176-183.	2.9	353
63	Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nature Medicine, 2002, 8, 1018-1023.	15.2	346
64	The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1359-1364.	3.3	345
65	Novel Lipid Mediators Promote Resolution of Acute Inflammation. Circulation Research, 2010, 107, 1170-1184.	2.0	338
66	A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor Î³ Inhibits Adipocyte Differentiation. Journal of Biological Chemistry, 2000, 275, 1873-1877.	1.6	337
67	Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nature Immunology, 2006, 7, 1209-1216.	7.0	331
68	Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. Journal of Experimental Medicine, 2008, 205, 2791-2801.	4.2	325
69	Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury. Journal of Immunology, 2006, 177, 5902-5911.	0.4	322
70	Identification of resolvin D2 receptor mediating resolution of infections and organ protection. Journal of Experimental Medicine, 2015, 212, 1203-1217.	4.2	320
71	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950â€“Metabolites in Frozen Human Plasma. Journal of Lipid Research, 2017, 58, 2275-2288.	2.0	312
72	Protectin D1 Is Generated in Asthma and Dampens Airway Inflammation and Hyperresponsiveness. Journal of Immunology, 2007, 178, 496-502.	0.4	311

#	Article	IF	Citations
73	Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils. Biochemistry, 1995, 34, 14609-14615.	1.2	309
74	Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids, 2004, 39, 1125-1132.	0.7	308
75	Emerging roles of resolvins in the resolution of inflammation and pain. Trends in Neurosciences, 2011, 34, 599-609.	4.2	298
76	Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nature Medicine, 2006, 12, 330-334.	15.2	286
77	Regulation of inflammation in cancer by eicosanoids. Prostaglandins and Other Lipid Mediators, 2011, 96, 27-36.	1.0	280
78	Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.. Journal of Experimental Medicine, 1996, 183, 137-146.	4.2	278
79	MicroRNAs in resolution of acute inflammation: identification of novel resolvin Dlâ€miRNA circuits. FASEB Journal, 2011, 25, 544-560.	0.2	276
80	Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Science Translational Medicine, 2016, 8, 353ra111.	5.8	273
81	Resolution phase lipid mediators of inflammation: agonists of resolution. Current Opinion in Pharmacology, 2013, 13, 632-640.	1.7	272
82	Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3902-3907.	3.3	271
83	International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors. Pharmacological Reviews, 2003, 55, 195-227.	7.1	271
84	Activation of Lipoxin a4 Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation. Journal of Experimental Medicine, 2000, 191, 1197-1208.	4.2	265
85	Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro.. Journal of Clinical Investigation, 1990, 85, 772-780.	3.9	263
86	Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins and Other Lipid Mediators, 2004, 73, 155-172.	1.0	260
87	Lipoxin biosynthesis and its impact in inflammatory and vascular events. Lipids and Lipid Metabolism, 1994, 1212, 1-25.	2.6	255
88	Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Molecular Aspects of Medicine, 2017, 58, 114-129.	2.7	255
89	Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15178-15183.	3.3	252
90	Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nature Immunology, 2002, 3, 76-82.	7.0	246

#	Article	IF	Citations
91	Resolution of Acute Inflammation in the Lung. Annual Review of Physiology, 2014, 76, 467-492.	5.6	246
92	Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. Journal of Clinical Investigation, 2011, 121, 569-581.	3.9	242
93	Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-ÂB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13266-13271.	3.3	240
94	Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E715-24.	3.3	240
95	Saturatedâ€efferocytosis generates proâ€resolving CD11b^{low} macrophages: Modulation by resolvins and glucocorticoids. European Journal of Immunology, 2011, 41, 366-379.	1.6	238
96	Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor. Journal of Biological Chemistry, 1997, 272, 6972-6978.	1.6	237
97	Signalling the fat controller. Nature, 1996, 384, 23-24.	13.7	236
98	Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins, 1997, 53, 107-137.	1.2	234
99	Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis. Journal of Biological Chemistry, 2010, 285, 3451-3461.	1.6	234
100	Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors. Current Topics in Medicinal Chemistry, 2011, 11, 629-647.	1.0	234
101	The novel 13S,14Sâ€epoxyâ€maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A₄hydrolase (LTA₄H), and shifts macrophage phenotype. FASEB Journal, 2013, 27, 2573-2583.	0.2	232
102	Specialized pro-resolving mediator network: an update on production and actions. Essays in Biochemistry, 2020, 64, 443-462.	2.1	231
103	Trihydroxytetraenes: A novel series of compounds formed from arachidonic acid in human leukocytes. Biochemical and Biophysical Research Communications, 1984, 118, 943-949.	1.0	230
104	Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAs. American Journal of Pathology, 2012, 180, 2018-2027.	1.9	224
105	Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat. Journal of Immunology, 2012, 189, 2597-2605.	0.4	222
106	Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8247-8252.	3.3	221
107	Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution. Journal of Immunology, 2008, 181, 8677-8687.	0.4	220
108	Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 163-177.	1.0	219

#	Article	IF	Citations
109	Resolvin D1 Limits Polymorphonuclear Leukocyte Recruitment to Inflammatory Loci. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1970-1978.	1.1	216
110	Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nature Medicine, 2015, 21, 1071-1075.	15.2	215
111	The Docosatriene Protectin D1 Is Produced by TH2 Skewing and Promotes Human T Cell Apoptosis via Lipid Raft Clustering. Journal of Biological Chemistry, 2005, 280, 43079-43086.	1.6	213
112	Resolvin E2: Identification and Anti-Inflammatory Actions: Pivotal Role of Human 5-Lipoxygenase in Resolvin E Series Biosynthesis. Chemistry and Biology, 2006, 13, 1193-1202.	6.2	212
113	Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nature Communications, 2018, 9, 59.	5.8	211
114	Resolvin D2 Is a Potent Endogenous Inhibitor for Transient Receptor Potential Subtype V1/A1, Inflammatory Pain, and Spinal Cord Synaptic Plasticity in Mice: Distinct Roles of Resolvin D1, D2, and E1. Journal of Neuroscience, 2011, 31, 18433-18438.	1.7	210
115	Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 40.	0.4	208
116	Resolving TRPV1- and TNF-Î±-Mediated Spinal Cord Synaptic Plasticity and Inflammatory Pain with Neuroprotectin D1. Journal of Neuroscience, 2011, 31, 15072-15085.	1.7	207
117	Identification of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon Î³ and Inhibits Tumor Necrosis Factor Î±â€“induced IL-8 Release. Journal of Experimental Medicine, 1998, 187, 1285-1294.	4.2	206
118	Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood, 2008, 112, 848-855.	0.6	204
119	Resolvin D1 and Aspirin-Triggered Resolvin D1 Promote Resolution of Allergic Airways Responses. Journal of Immunology, 2012, 189, 1983-1991.	0.4	204
120	Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents. Chemistry and Biology, 2013, 20, 188-201.	6.2	204
121	Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1Î±â€“initiated Neutrophil Responses and Trafficking: Regulators of a Cytokineâ€“Chemokine Axis. Journal of Experimental Medicine, 1999, 189, 1923-1930.	4.2	202
122	Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.. Journal of Clinical Investigation, 1998, 101, 819-826.	3.9	202
123	Resolvins suppress tumor growth and enhance cancer therapy. Journal of Experimental Medicine, 2018, 215, 115-140.	4.2	200
124	15-Epi-lipoxin A₄Inhibits Myeloperoxidase Signaling and Enhances Resolution of Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 311-319.	2.5	199
125	Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers.. Journal of Clinical Investigation, 1993, 92, 75-82.	3.9	199
126	Novel n-3 Immunoresolvents: Structures and Actions. Scientific Reports, 2013, 3, 1940.	1.6	197

#	Article	IF	Citations
127	Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. Journal of Clinical Investigation, 1999, 104, 309-316.	3.9	197
128	Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. Journal of Molecular and Cellular Cardiology, 2015, 84, 24-35.	0.9	194
129	Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB Journal, 2007, 21, 3162-3170.	0.2	193
130	Lipoxin A4Analogues Inhibit Leukocyte Recruitment toPorphyromonas gingivalis:Â A Role for Cyclooxygenase-2 and Lipoxins in Periodontal Diseaseâ€. Biochemistry, 2000, 39, 4761-4768.	1.2	191
131	Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy.. Circulation, 1992, 86, 56-63.	1.6	189
132	The opportunistic pathogenPseudomonas aeruginosacarries a secretable arachidonate 15-lipoxygenase. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2135-2139.	3.3	189
133	Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Molecular Aspects of Medicine, 2017, 58, 1-11.	2.7	188
134	New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Molecular Aspects of Medicine, 2018, 64, 1-17.	2.7	186
135	Cutting Edge: Humanized Nano-Proresolving Medicines Mimic Inflammation-Resolution and Enhance Wound Healing. Journal of Immunology, 2011, 186, 5543-5547.	0.4	185
136	Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 115-121.	1.3	184
137	Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)â€“Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation. Molecular Medicine, 1996, 2, 583-596.	1.9	183
138	Aspirin-Triggered Lipoxin A4 and B4 Analogs Block Extracellular Signal-Regulated Kinase-Dependent TNF-Î± Secretion from Human T Cells. Journal of Immunology, 2003, 170, 6266-6272.	0.4	182
139	Impaired Local Production of Proresolving Lipid Mediators in Obesity and 17-HDHA as a Potential Treatment for Obesity-Associated Inflammation. Diabetes, 2013, 62, 1945-1956.	0.3	181
140	Lipoxins and new lipid mediators in the resolution of inflammation. Current Opinion in Pharmacology, 2006, 6, 414-420.	1.7	180
141	Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. American Journal of Pathology, 2010, 177, 2116-2123.	1.9	178
142	Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins.. Journal of Clinical Investigation, 1993, 92, 1572-1579.	3.9	177
143	Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses. American Journal of Pathology, 2001, 158, 3-9.	1.9	176
144	Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils.. Journal of Experimental Medicine, 1990, 172, 1451-1457.	4.2	175

#	Article	IF	Citations
145	Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB Journal, 2003, 17, 652-659.	0.2	174
146	A Novel Anti-Inflammatory and Pro-Resolving Role for Resolvin D1 in Acute Cigarette Smoke-Induced Lung Inflammation. PLoS ONE, 2013, 8, e58258.	1.1	174
147	Novel ? ? 3-derived local mediators in anti-inflammation and resolution. , 2005, 105, 7-21.		173
148	Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LCâ€“MS/MS. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 1415-1424.	1.2	173
149	Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. British Journal of Pharmacology, 2014, 171, 3551-3574.	2.7	173
150	Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. European Respiratory Journal, 2000, 16, 44-49.	3.1	171
151	The resolution of inflammation: the devil in the flask and in the details. FASEB Journal, 2011, 25, 1441-1448.	0.2	171
152	Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. Cell Metabolism, 2015, 22, 125-137.	7.2	170
153	Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins and Other Lipid Mediators, 2002, 68-69, 433-455.	1.0	169
154	Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?. Cancer and Metastasis Reviews, 2020, 39, 337-340.	2.7	169
155	Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. Journal of Experimental Medicine, 2007, 204, 245-252.	4.2	166
156	Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. Journal of Immunology, 1996, 156, 2264-72.	0.4	166
157	Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6248-6252.	3.3	165
158	Oxidoreductases in Lipoxin A4 Metabolic Inactivation. Journal of Biological Chemistry, 2000, 275, 25372-25380.	1.6	165
159	Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. Progress in Lipid Research, 2022, 86, 101165.	5.3	164
160	Novel Lipid Mediator Regulators of Endothelial Cell Proliferation and Migration: Aspirin-Triggered-15R-Lipoxin A4 and Lipoxin A4. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 385-392.	1.3	163
161	New Lives Given by Cell Death: Macrophage Differentiation Following Their Encounter with Apoptotic Leukocytes during the Resolution of Inflammation. Frontiers in Immunology, 2012, 3, 4.	2.2	163
162	Altered Fatty Acid Composition of Dopaminergic Neurons Expressing Î±-Synuclein and Human Brains with Î±-Synucleinopathies. Journal of Biological Chemistry, 2003, 278, 49874-49881.	1.6	160

#	Article	IF	Citations
163	Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes. Critical Care Medicine, 2017, 45, 58-68.	0.4	160
164	Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. Journal of Clinical Investigation, 2019, 129, 5294-5311.	3.9	158
165	Resolvin E2 Formation and Impact in Inflammation Resolution. Journal of Immunology, 2012, 188, 4527-4534.	0.4	157
166	Cutting Edge: Maresin-1 Engages Regulatory T Cells To Limit Type 2 Innate Lymphoid Cell Activation and Promote Resolution of Lung Inflammation. Journal of Immunology, 2015, 194, 863-867.	0.4	155
167	Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase AÎ²42 Phagocytosis. Molecular Neurobiology, 2016, 53, 2733-2749.	1.9	152
168	A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochemistry and Cell Biology, 2004, 122, 305-321.	0.8	151
169	Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight, 2016, 1, e85922.	2.3	150
170	Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs.. Journal of Clinical Investigation, 1998, 101, 1860-1869.	3.9	147
171	Lipoxin A. Stereochemistry and biosynthesis.. Journal of Biological Chemistry, 1986, 261, 16340-16345.	1.6	146
172	Novel Proresolving Aspirin-Triggered DHA Pathway. Chemistry and Biology, 2011, 18, 976-987.	6.2	145
173	Maresin 1 biosynthesis during plateletâ€“neutrophil interactions is organ-protective. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16526-16531.	3.3	144
174	Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodiumâ€“induced colitis. Inflammatory Bowel Diseases, 2010, 16, 87-95.	0.9	143
175	Vagus nerve controls resolution and pro-resolving mediators of inflammation. Journal of Experimental Medicine, 2014, 211, 1037-1048.	4.2	143
176	Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3438-3442.	3.3	142
177	Identification of Lipoxin A₄and Its Relationship to the Sulfidopeptide Leukotrienes C₄, D₄, and E₄in the Bronchoalveolar Lavage Fluids Obtained from Patients with Selected Pulmonary Diseases. The American Review of Respiratory Disease, 1990, 141, 1453-1458.	2.9	142
178	Unesterified docosahexaenoic acid is protective in neuroinflammation. Journal of Neurochemistry, 2013, 127, 378-393.	2.1	140
179	Plasma Metabolomics in Human Pulmonary Tuberculosis Disease: A Pilot Study. PLoS ONE, 2014, 9, e108854.	1.1	140
180	Metabolic Inactivation of Resolvin E1 and Stabilization of Its Anti-inflammatory Actions. Journal of Biological Chemistry, 2006, 281, 22847-22854.	1.6	139

#	Article	IF	Citations
181	Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. Journal of Thrombosis and Haemostasis, 2009, 7, 44-48.	1.9	138
182	Anti-angiogenesis Effect of the Novel Anti-inflammatory and Pro-resolving Lipid Mediators. , 2009, 50, 4743.		137
183	Resolution of inflammation: An organizing principle in biology and medicine. , 2021, 227, 107879.		137
184	International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions. Pharmacological Reviews, 2011, 63, 539-584.	7.1	134
185	Protectin D1 _{n-3 DPA} and resolvin D5 _{n-3 DPA} are effectors of intestinal protection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3963-3968.	3.3	134
186	Aging Delays Resolution of Acute Inflammation in Mice: Reprogramming the Host Response with Novel Nano-Proresolving Medicines. Journal of Immunology, 2014, 193, 4235-4244.	0.4	131
187	Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. Journal of Clinical Investigation, 2001, 107, 1481-1489.	3.9	130
188	Maresin Biosynthesis and Identification of Maresin 2, a New Anti-Inflammatory and Pro-Resolving Mediator from Human Macrophages. PLoS ONE, 2014, 9, e102362.	1.1	130
189	Lipoxin A. Stereochemistry and biosynthesis. Journal of Biological Chemistry, 1986, 261, 16340-5.	1.6	130
190	Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1. PLoS ONE, 2011, 6, e24422.	1.1	129
191	Aspirin-Triggered Lipoxins Override the Apoptosis-Delaying Action of Serum Amyloid A in Human Neutrophils: A Novel Mechanism for Resolution of Inflammation. Journal of Immunology, 2007, 179, 616-622.	0.4	128
192	Lipoxin A4 Receptor Activation Is Distinct from That of the Formyl Peptide Receptor in Myeloid Cells: Inhibition of CD11/18 Expression by Lipoxin A4-Lipoxin A4 Receptor Interaction. Biochemistry, 1995, 34, 16678-16686.	1.2	127
193	Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxyâ€fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 75-83.	0.7	127
194	Novel Resolvin D2 Receptor Axis in Infectious Inflammation. Journal of Immunology, 2017, 198, 842-851.	0.4	127
195	Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinsonâ€™s disease. Nature Communications, 2019, 10, 3945.	5.8	127
196	Cyclooxygenase-2-Derived Prostaglandin E2 and Lipoxin A4 Accelerate Resolution of Allergic Edema inAngiostrongylus costaricensis-Infected Rats: Relationship with Concurrent Eosinophilia. Journal of Immunology, 2000, 164, 1029-1036.	0.4	126
197	NLRP3 Inflammasome Deficiency Protects against Microbial Sepsis via Increased Lipoxin B₄Synthesis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 713-726.	2.5	126
198	Melanoma growth is reduced in fat-1 transgenic mice: Impact of omega-6/omega-3 essential fatty acids. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12499-12504.	3.3	125

#	Article	IF	Citations
199	Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochemical Journal, 2011, 437, 185-197.	1.7	125
200	Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. British Journal of Pharmacology, 2004, 143, 43-52.	2.7	124
201	Leukotriene B 4 and lipoxin A 4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB Journal, 2006, 20, 1785-1792.	0.2	124
202	Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTR1 Controls Infection Resolution. Immunity, 2017, 46, 92-105.	6.6	122
203	Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Frontiers in Immunology, 2017, 8, 1400.	2.2	120
204	Specialized Proresolving Mediators Enhance Human B Cell Differentiation to Antibody-Secreting Cells. Journal of Immunology, 2012, 189, 1036-1042.	0.4	118
205	Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Frontiers in Immunology, 2012, 3, 298.	2.2	118
206	The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: Novel oxygenase products from Ï‰-3 polyunsaturated fatty acids. Biochemical and Biophysical Research Communications, 2005, 338, 149-157.	1.0	115
207	Resolvin E1 and Chemokine-like Receptor 1 Mediate Bone Preservation. Journal of Immunology, 2013, 190, 689-694.	0.4	115
208	Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking. Journal of Immunology, 2000, 164, 2267-2271.	0.4	114
209	Proresolving Nanomedicines Activate Bone Regeneration in Periodontitis. Journal of Dental Research, 2015, 94, 148-156.	2.5	114
210	Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney International, 1995, 47, 1295-1302.	2.6	113
211	Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. Journal of Lipid Research, 2010, 51, 2018-2031.	2.0	113
212	Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators. Immunity, 2013, 39, 885-898.	6.6	113
213	Diversity of lipid mediators in human adipose tissue depots. American Journal of Physiology - Cell Physiology, 2013, 304, C1141-C1149.	2.1	112
214	Dâ€series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB Journal, 2013, 27, 2220-2232.	0.2	112
215	Lipoxin A4 and Aspirin-Triggered 15-epi-Lipoxin A4 Inhibit Human Neutrophil Migration: Comparisons Between Synthetic 15 Epimers in Chemotaxis and Transmigration with Microvessel Endothelial Cells and Epithelial Cells. Journal of Immunology, 2003, 170, 2688-2694.	0.4	111
216	An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. British Journal of Pharmacology, 2008, 155, 1214-1223.	2.7	110

#	Article	IF	Citations
217	Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB Journal, 2016, 30, 2792-2801.	0.2	110
218	Aspirin-triggered proresolving mediators stimulate resolution in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6292-6297.	3.3	110
219	The Atlas of Inflammation Resolution (AIR). Molecular Aspects of Medicine, 2020, 74, 100894.	2.7	110
220	Identification and structure elucidation of the proâ€resolving mediators provides novel leads for resolution pharmacology. British Journal of Pharmacology, 2019, 176, 1024-1037.	2.7	108
221	The Specialized Proresolving Mediator 17-HDHA Enhances the Antibody-Mediated Immune Response against Influenza Virus: A New Class of Adjuvant?. Journal of Immunology, 2014, 193, 6031-6040.	0.4	107
222	Conjunctival Goblet Cell Secretion Stimulated by Leukotrienes Is Reduced by Resolvins D1 and E1 To Promote Resolution of Inflammation. Journal of Immunology, 2011, 186, 4455-4466.	0.4	106
223	Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Unique Proresolving Mediatorâ€“Heme Oxygenase-1 Circuits. Journal of Immunology, 2013, 190, 6378-6388.	0.4	106
224	Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. Journal of Immunology, 2016, 197, 2362-2368.	0.4	106
225	Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunology, 2016, 9, 757-766.	2.7	106
226	Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. Journal of Biological Chemistry, 1992, 267, 16168-76.	1.6	105
227	Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: Conversion to novel 15-oxo and dihydro products. Biochemistry, 1993, 32, 6313-6319.	1.2	104
228	Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: Role of P-selectin. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9967-9972.	3.3	104
229	Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a â€˜stopâ€™ signaling switch for aspirinâ€triggered lipoxin A₄. FASEB Journal, 1999, 13, 903-911.	0.2	104
230	Candida albicans Modulates Host Defense by Biosynthesizing the Pro-Resolving Mediator Resolvin E1. PLoS ONE, 2007, 2, e1316.	1.1	104
231	Lipoxin A₄stable analogs reduce allergic airway responsesviamechanisms distinct from CysLT1 receptor antagonism. FASEB Journal, 2007, 21, 3877-3884.	0.2	102
232	Self-Limited versus Delayed Resolution of Acute Inflammation: Temporal Regulation of Pro-Resolving Mediators and MicroRNA. Scientific Reports, 2012, 2, 639.	1.6	102
233	Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve trauma. Annals of Neurology, 2013, 74, 490-495.	2.8	102
234	Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution. Journal of Immunology, 2008, 180, 3512-3519.	0.4	101

#	Article	IF	Citations
235	Anesthetics Impact the Resolution of Inflammation. PLoS ONE, 2008, 3, e1879.	1.1	101
236	Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4753-61.	3.3	101
237	Carcinogenesis: Failure of resolution of inflammation?. , 2021, 218, 107670.		101
238	Cutting Edge: Nociceptin Stimulates Neutrophil Chemotaxis and Recruitment: Inhibition by Aspirin-Triggered-15-Epi-Lipoxin A4. Journal of Immunology, 2001, 166, 3650-3654.	0.4	100
239	Novel proresolving and tissueâ€regenerative resolvin and protectin sulfidoâ€conjugated pathways. FASEB Journal, 2015, 29, 2120-2136.	0.2	100
240	Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics. Prostaglandins Leukotrienes and Essential Fatty Acids, 2017, 117, 17-27.	1.0	99
241	A Molecular Defect in Intracellular Lipid Signaling in Human Neutrophils in Localized Aggressive Periodontal Tissue Damage. Journal of Immunology, 2004, 172, 1856-1861.	0.4	98
242	Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Experimental Neurology, 2012, 236, 122-130.	2.0	98
243	Controlling the Resolution of Acute Inflammation: A New Genus of Dual Antiâ€inflammatory and Proresolving Mediators. Journal of Periodontology, 2008, 79, 1520-1526.	1.7	97
244	Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2005-2013.	1.1	96
245	Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome. FASEB Journal, 2019, 33, 6140-6153.	0.2	95
246	Changes in phosphatidylinositol and phosphatidic acid in stimulated human neutrophils. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 762, 420-428.	1.9	94
247	Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1. Pain, 2011, 152, 557-565.	2.0	94
248	Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. Journal of Clinical Investigation, 2019, 129, 2964-2979.	3.9	94
249	Lipoxin B₄regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B₄analogs with increased biologic activity. FASEB Journal, 1998, 12, 487-494.	0.2	92
250	Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukotrienes and Essential Fatty Acids, 2010, 82, 27-34.	1.0	92
251	Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. Journal of the American Society for Mass Spectrometry, 2007, 18, 128-144.	1.2	91
252	Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20560-20565.	3.3	91

#	Article	IF	Citations
253	Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8609-8611.	3.3	90
254	Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunology, 2010, 3, 270-279.	2.7	90
255	Splenic leukocytes define the resolution of inflammation in heart failure. Science Signaling, 2018, 11, .	1.6	90
256	Anti-Inflammatory Actions of Lipoxin A4 Stable Analogs Are Demonstrable in Human Whole Blood: Modulation of Leukocyte Adhesion Molecules and Inhibition of Neutrophil-Endothelial Interactions. Blood, 1999, 94, 4132-4142.	0.6	90
257	Metabolomicsâ€Lipidomics of Eicosanoids and Docosanoids Generated by Phagocytes. Current Protocols in Immunology, 2011, 95, Unit 14.26.	3.6	88
258	Novel Chemical Mediators in the Resolution of Inflammation: Resolvins and Protectins. Anesthesiology Clinics, 2006, 24, 341-364.	1.4	87
259	Total Synthesis of the Lipid Mediator PD1_{n-3ÂDPA}: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions. Journal of Natural Products, 2014, 77, 910-916.	1.5	87
260	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. Journal of Immunology, 2016, 197, 3360-3370.	0.4	87
261	A novel rat lipoxin A4 receptor that is conserved in structure and function. British Journal of Pharmacology, 2003, 139, 89-98.	2.7	86
262	Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB Journal, 2010, 24, 906-915.	0.2	86
263	Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. Journal of Pharmacology and Experimental Therapeutics, 1998, 287, 779-90.	1.3	86
264	Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entrÃ©e for resoleomics. Rheumatic Disease Clinics of North America, 2004, 30, 69-95.	0.8	85
265	The Protectin PCTR1 Is Produced by Human M2 Macrophages and Enhances Resolution of Infectious Inflammation. American Journal of Pathology, 2016, 186, 962-973.	1.9	83
266	Formation of leukotrienes and hydroxy acids by human neutrophils and platelets exposed to monosodium urate. Prostaglandins, 1984, 27, 563-581.	1.2	82
267	Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins. Stem Cells Translational Medicine, 2016, 5, 20-32.	1.6	82
268	Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: Inhibition by antibodies against CD18 and L-selectin. Biochemical and Biophysical Research Communications, 1992, 186, 1307-1314.	1.0	81
269	Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukotrienes and Essential Fatty Acids, 2008, 79, 157-163.	1.0	81
270	Resolvin D4 stereoassignment and its novel actions in host protection and bacterial clearance. Scientific Reports, 2016, 6, 18972.	1.6	81

#	Article	IF	Citations
271	Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation. Mucosal Immunology, 2016, 9, 1278-1287.	2.7	81
272	Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Letters, 1989, 245, 167-172.	1.3	80
273	Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochemical Journal, 1993, 296, 127-133.	1.7	80
274	Profiling in resolving inflammatory exudates identifies novel antiâ€inflammatory and proâ€resolving mediators and signals for termination. Journal of Internal Medicine, 2010, 268, 15-24.	2.7	80
275	Resolvin D1 controls inflammation initiated by glutathioneâ€lipid conjugates formed during oxidative stress. British Journal of Pharmacology, 2009, 158, 1062-1073.	2.7	79
276	Decoding Functional Metabolomics with Docosahexaenoyl Ethanolamide (DHEA) Identifies Novel Bioactive Signals. Journal of Biological Chemistry, 2011, 286, 31532-31541.	1.6	79
277	Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L888-L901.	1.3	79
278	Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12232-12237.	3.3	79
279	Formation of lipoxin A by granulocytes from eosinophilic donors. FEBS Letters, 1987, 217, 242-246.	1.3	78
280	A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. JCI Insight, 2018, 3, .	2.3	78
281	Lipoxin generation by permeabilized human platelets. Biochemistry, 1992, 31, 8269-8277.	1.2	77
282	The Protectin Family of Specialized Pro-resolving Mediators: Potent Immunoresolvents Enabling Innovative Approaches to Target Obesity and Diabetes. Frontiers in Pharmacology, 2018, 9, 1582.	1.6	77
283	On the relationship between leukotriene and lipoxin production by human neutrophils: evidence for differential metabolism of 15-HETE and 5-HETE. Lipids and Lipid Metabolism, 1989, 1004, 158-168.	2.6	76
284	Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Brazilian Journal of Medical and Biological Research, 2001, 34, 555-566.	0.7	76
285	Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunology, 2013, 6, 1119-1130.	2.7	76
286	Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectinsâ€"Mediator lipidomic analysis. Prostaglandins and Other Lipid Mediators, 2005, 78, 107-116.	1.0	75
287	New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nature Clinical Practice Rheumatology, 2007, 3, 570-579.	3.2	75
288	Microscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming. Nature Biomedical Engineering, 2017, 1, .	11.6	74

#	Article	IF	Citations
289	Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Molecular Medicine, 1996, 2, 583-96.	1.9	74
290	A mosquito lipoxin/lipocalin complex mediates innate immune priming in Anopheles gambiae. Nature Communications, 2015, 6, 7403.	5.8	73
291	Maresin 1 Biosynthesis and Proresolving Anti-infective Functions with Human-Localized Aggressive Periodontitis Leukocytes. Infection and Immunity, 2016, 84, 658-665.	1.0	72
292	Lipoxin <scp>A</scp>₄ modulates adaptive immunity by decreasing memory <scp>B</scp>â€cell responses via an <scp>ALX</scp>/<scp>FPR</scp>2â€dependent mechanism. European Journal of Immunology, 2014, 44, 357-369.	1.6	71
293	Resolvin D5 Inhibits Neuropathic and Inflammatory Pain in Male But Not Female Mice: Distinct Actions of D-Series Resolvins in Chemotherapy-Induced Peripheral Neuropathy. Frontiers in Pharmacology, 2019, 10, 745.	1.6	71
294	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica, 2020, 105, 2056-2070.	1.7	70
295	Resolvin D1 Reduces Emphysema and Chronic Inflammation. American Journal of Pathology, 2015, 185, 3189-3201.	1.9	69
296	Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes. Journal of Immunology, 2017, 198, 718-728.	0.4	69
297	Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Scientific Reports, 2018, 8, 18050.	1.6	69
298	Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood, 2019, 134, 1458-1468.	0.6	69
299	Mediator lipidomics. Prostaglandins and Other Lipid Mediators, 2005, 77, 4-14.	1.0	68
300	Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. Frontiers in Pharmacology, 2018, 9, 412.	1.6	68
301	Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: Dissociation between lipid remodeling and adhesion. Journal of Cellular Physiology, 1990, 143, 512-523.	2.0	67
302	Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omegaâ€3 intake. American Journal of Hematology, 2008, 83, 437-445.	2.0	67
303	Aspirin Has A Gender-Dependent Impact on Antiinflammatory 15-Epi-Lipoxin A 4 Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e14-7.	1.1	66
304	Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coliâ€“driven acute inflammation. JCI Insight, 2018, 3, .	2.3	66
305	Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis. Methods in Molecular Biology, 2018, 1730, 59-72.	0.4	65
306	Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins. Scientific World Journal, The, 2002, 2, 169-204.	0.8	64

#	Article	IF	Citations
307	Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation. Journal of Immunology, 2016, 197, 4444-4452.	0.4	64
308	Stretching Impacts Inflammation Resolution in Connective Tissue. Journal of Cellular Physiology, 2016, 231, 1621-1627.	2.0	64
309	15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-Î²B Regulators in Bacterial Pneumonia. Journal of Immunology, 2018, 200, 2757-2766.	0.4	63
310	Tollâ€like receptor 7 stimulates production of specialized proâ€resolving lipid mediators and promotes resolution of airway inflammation. EMBO Molecular Medicine, 2013, 5, 762-775.	3.3	62
311	Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L904-L911.	1.3	62
312	LXA₄, aspirin-triggered 15-epi-LXA₄, and their analogs selectively downregulate PMN azurophilic degranulation. American Journal of Physiology - Cell Physiology, 1999, 276, C988-C994.	2.1	61
313	Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. Journal of Physiology and Pharmacology, 2000, 51, 643-54.	1.1	61
314	Intravascular filarial parasites elaborate cyclooxygenase-derived eicosanoids.. Journal of Experimental Medicine, 1990, 172, 993-996.	4.2	60
315	A Stable Aspirin-Triggered Lipoxin A4 Analog Blocks Phosphorylation of Leukocyte-Specific Protein 1 in Human Neutrophils. Journal of Immunology, 2004, 173, 2091-2098.	0.4	60
316	Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. Journal of Lipid Research, 2005, 46, 790-802.	2.0	60
317	Formation of Endogenous â€œAntiinflammatoryâ€•Lipid Mediators by Transcellular Biosynthesis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S95-S101.	2.5	59
318	Aspirinâ€triggered lipoxin A 4 and lipoxin A 4 upâ€regulate transcriptional corepressor NAB1 in human neutrophils. FASEB Journal, 2001, 15, 1-18.	0.2	59
319	Polyisoprenyl phosphates in intracellular signalling. Nature, 1997, 389, 985-990.	13.7	58
320	Biosynthesis of D-Series Resolvins in SkinÂProvides Insights into their Role inÂTissue Repair. Journal of Investigative Dermatology, 2018, 138, 2051-2060.	0.3	58
321	Adipocytes promote ovarian cancer chemoresistance. Scientific Reports, 2019, 9, 13316.	1.6	58
322	Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight, 2016, 1, .	2.3	58
323	Antimicrobial Aspects of Inflammatory Resolution in the Mucosa: A Role for Proresolving Mediators. Journal of Immunology, 2011, 187, 3475-3481.	0.4	57
324	Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 301-321.	1.0	56

#	Article	IF	Citations
325	Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1382-1387.	1.0	56
326	The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 314-325.	1.4	56
327	Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators*. Critical Care Medicine, 2016, 44, e1236-e1245.	0.4	56
328	The action of Lipoxin-A on glomerular microcirculatory dynamics in the rat. Biochemical and Biophysical Research Communications, 1987, 145, 408-414.	1.0	55
329	Total Synthesis of the Antiâ€inflammatory and Proâ€resolving Lipid Mediator MaR1_{nâ€™3 DPA} Utilizing an sp³â€“sp³ Negishi Crossâ€Coupling Reaction. Chemistry - A European Journal, 2014, 20, 14575-14578.	1.7	55
330	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. Lipids, 1993, 28, 1047-1053.	0.7	54
331	The Resolvin D1 Analogue Controls Maturation of Dendritic Cells and Suppresses Alloimmunity in Corneal Transplantation. , 2014, 55, 5944.		54
332	Identification and Actions of a Novel Third Maresin Conjugate in Tissue Regeneration: MCTR3. PLoS ONE, 2016, 11, e0149319.	1.1	54
333	A cluster of immunoresolvents links coagulation to innate host defense in human blood. Science Signaling, 2017, 10, .	1.6	54
334	Immune responsive resolvin D1 programs myocardial infarctionâ€induced cardiorenal syndrome in heart failure. FASEB Journal, 2018, 32, 3717-3729.	0.2	54
335	Lipoxin Biosynthesis by Trout Macrophages Involves the Formation of Epoxide Intermediates. Biochemistry, 1994, 33, 856-863.	1.2	52
336	Lipoxin A4 activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion. Mucosal Immunology, 2017, 10, 46-57.	2.7	52
337	Potent Antiâ€inflammatory and Proâ€Resolving Effects of Anabasum in a Human Model of Selfâ€Resolving Acute Inflammation. Clinical Pharmacology and Therapeutics, 2018, 104, 675-686.	2.3	52
338	Anti-inflammatory and pro-resolving properties of benzo-lipoxin A4 analogs. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 357-366.	1.0	51
339	17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and liveE. coli. Journal of Leukocyte Biology, 2011, 90, 459-470.	1.5	51
340	Resolvin D3 multi-level proresolving actions are host protective during infection. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 138, 81-89.	1.0	51
341	Dexamethasone, proâ€resolving lipid mediators and resolution of inflammation in COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 626-628.	2.7	51
342	Contributions of the Three CYP1 Monooxygenases to Pro-Inflammatory and Inflammation-Resolution Lipid Mediator Pathways. Journal of Immunology, 2013, 191, 3347-3357.	0.4	50

#	Article	IF	Citations
343	Resolution metabolomes activated by hypoxic environment. Science Advances, 2019, 5, eaax4895.	4.7	50
344	Resolution of sickle cell diseaseâ€“associated inflammation and tissue damage with 17R-resolvin D1. Blood, 2019, 133, 252-265.	0.6	50
345	Chemical Mediators of Inflammation and Resolution in Post-Operative Abdominal Aortic Aneurysm Patients. Inflammation, 2012, 35, 98-113.	1.7	49
346	Cutting Edge: Parathyroid Hormone Facilitates Macrophage Efferocytosis in Bone Marrow via Proresolving Mediators Resolvin D1 and Resolvin D2. Journal of Immunology, 2014, 193, 26-29.	0.4	49
347	Identification and Complete Stereochemical Assignments of the New Resolvin Conjugates in Tissue Regeneration in Human Tissues that Stimulate Proresolving Phagocyte Functions and Tissue Regeneration. American Journal of Pathology, 2018, 188, 950-966.	1.9	49
348	Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. Biochemical Society Transactions, 2003, 31, 795-800.	1.6	48
349	Stereocontrolled Total Synthesis of the Potent Anti-inflammatory and Pro-resolving Lipid Mediator Resolvin D3 and Its Aspirin-Triggered 17R-Epimer. Organic Letters, 2013, 15, 1424-1427.	2.4	48
350	The Scent of a Phagocyte. Journal of Experimental Medicine, 2000, 192, F5-F8.	4.2	47
351	Chiral lipidomics of E-series resolvins: Aspirin and the biosynthesis of novel mediators. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 737-747.	1.2	47
352	Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia. American Journal of Pathology, 2016, 186, 1801-1813.	1.9	47
353	Targeting lipid mediators in cancer biology. Cancer and Metastasis Reviews, 2018, 37, 557-572.	2.7	47
354	Staphylococcus aureus-Derived Î±-Hemolysin Evokes Generation of Specialized Pro-resolving Mediators Promoting Inflammation Resolution. Cell Reports, 2020, 33, 108247.	2.9	47
355	Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 87-93.	1.0	46
356	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A₄. American Journal of Physiology - Cell Physiology, 1999, 277, C870-C877.	2.1	46
357	COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 339-343.	1.0	46
358	Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. Journal of Experimental Medicine, 2008, 205, 1077-1086.	4.2	46
359	Resolution of Inflammation in Asthma. Clinics in Chest Medicine, 2012, 33, 559-570.	0.8	46
360	Molecular and Cellular Differences in Cardiac Repair of Male and Female Mice. Journal of the American Heart Association, 2020, 9, e015672.	1.6	46

#	Article	IF	Citations
361	Transcellular Regulation of Eicosanoid Biosynthesis. , 1999, 120, 119-144.		45
362	IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4267-4272.	3.3	45
363	Expression of 5-lipoxygenase in pulmonary artery endothelial cells. Biochemical Journal, 2002, 361, 267-276.	1.7	45
364	The novel lipid mediator PD1n-3 DPA: An overview of the structural elucidation, synthesis, biosynthesis and bioactions. Prostaglandins and Other Lipid Mediators, 2017, 133, 103-110.	1.0	45
365	Tonic inhibition of chemotaxis in human plasma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17949-17954.	3.3	44
366	Protective Actions of Aspirin-Triggered (17R) Resolvin D1 and Its Analogue, 17R-Hydroxy-19-Para-Fluorophenoxy-Resolvin D1 Methyl Ester, in C5a-Dependent IgG Immune Complexâ€“Induced Inflammation and Lung Injury. Journal of Immunology, 2014, 193, 3769-3778.	0.4	44
367	The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. Prostaglandins Leukotrienes and Essential Fatty Acids, 2011, 84, 43-50.	1.0	43
368	Neuroprotectin/protectin D1: endogenous biosynthesis and actions on diabetic macrophages in promoting wound healing and innervation impaired by diabetes. American Journal of Physiology - Cell Physiology, 2014, 307, C1058-C1067.	2.1	43
369	Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation. Journal of Internal Medicine, 2019, 286, 240-258.	2.7	43
370	Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. Molecular Metabolism, 2020, 31, 138-149.	3.0	43
371	Lipoxins: Eicosanoids carrying intra-and intercellular messages. Journal of Bioenergetics and Biomembranes, 1991, 23, 105-122.	1.0	43
372	Mediator Lipidomics: Search Algorithms for Eicosanoids, Resolvins, and Protectins. Methods in Enzymology, 2007, 432, 275-317.	0.4	42
373	Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and antiâ€inflammatory eicosanoid, lipoxin A4. FASEB Journal, 2009, 23, 1503-1509.	0.2	42
374	Functional Metabolomics Reveals Novel Active Products in the DHA Metabolome. Frontiers in Immunology, 2012, 3, 81.	2.2	42
375	Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: Stabilization of eicosanoids by liposomes. Biochemical and Biophysical Research Communications, 1989, 159, 477-481.	1.0	41
376	Lipoxin A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor-alpha-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. Journal of Periodontal Research, 1999, 34, 370-373.	1.4	41
377	Endogenous Receptor Agonists: Resolving Inflammation. Scientific World Journal, The, 2007, 7, 1440-1462.	0.8	41
378	Stereocontrolled total synthesis of Neuroprotectin D1/Protectin D1 and its aspirin-triggered stereoisomer. Tetrahedron Letters, 2012, 53, 1695-1698.	0.7	41

#	Article	IF	Citations
379	Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. Critical Care Medicine, 2015, 43, 2642-2650.	0.4	41
380	Cutting Edge: Human Vagus Produces Specialized Proresolving Mediators of Inflammation with Electrical Stimulation Reducing Proinflammatory Eicosanoids. Journal of Immunology, 2018, 201, 3161-3165.	0.4	41
381	Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1133, 223-234.	1.9	40
382	Identification of Dual Cyclooxygenaseâ€“Eicosanoid Oxidoreductase Inhibitors: NSAIDs That Inhibit PG-LX Reductase/LTB4 Dehydrogenase. Biochemical and Biophysical Research Communications, 2001, 288, 868-874.	1.0	40
383	Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions. Blood, 1999, 94, 4132-42.	0.6	40
384	Synthesis and Anti-inflammatory and Pro-resolving Activities of 22-OH-PD1, a Monohydroxylated Metabolite of Protectin D1. Journal of Natural Products, 2014, 77, 2241-2247.	1.5	39
385	Synthesis of the 16S,17S-Epoxyprotectin Intermediate in the Biosynthesis of Protectins by Human Macrophages. Journal of Natural Products, 2015, 78, 2924-2931.	1.5	39
386	Identification of proresolving and inflammatory lipid mediators in human psoriasis. Journal of Clinical Lipidology, 2018, 12, 1047-1060.	0.6	38
387	Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9252-9257.	3.3	38
388	Cysteinyl maresins regulate the prophlogistic lung actions of cysteinyl leukotrienes. Journal of Allergy and Clinical Immunology, 2020, 145, 335-344.	1.5	38
389	Evidence for a 5(6)-epoxytetraene intermediate in the biosynthesis of lipoxins in human leukocytes. FEBS Letters, 1986, 207, 127-132.	1.3	37
390	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB Journal, 2006, 20, 1097-1108.	0.2	37
391	Nutrigenetic Disruption of Inflammation-Resolution Homeostasis and Atherogenesis. Journal of Nutrigenetics and Nutrigenomics, 2011, 4, 12-24.	1.8	37
392	Atherosclerosis, Periodontal Disease, and Treatment with Resolvins. Current Atherosclerosis Reports, 2017, 19, 57.	2.0	37
393	A synthetic eicosanoid LXâ€mimetic unravels hostâ€donor interactions in allogeneic BMTâ€induced GvHD to reveal an early protective role for host neutrophils. FASEB Journal, 2005, 19, 203-210.	0.2	36
394	Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L746-L757.	1.3	36
395	ERV1 Overexpression in Myeloid Cells Protects against High Fat Diet Induced Obesity and Glucose Intolerance. Scientific Reports, 2017, 7, 12848.	1.6	36
396	Resolvin T-series reduce neutrophil extracellular traps. Blood, 2022, 139, 1222-1233.	0.6	36

#	Article	IF	Citations
397	New maresin conjugates in tissue regeneration pathway counters leukotriene D₄â€“stimulated vascular responses. FASEB Journal, 2018, 32, 4043-4052.	0.2	35
398	Novel Pathways and Endogenous Mediators in Anti-Inflammation and Resolution. , 2003, 83, 115-145.		34
399	Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukotrienes and Essential Fatty Acids, 2012, 87, 127-134.	1.0	34
400	Eicosanoids in leukocyte function. Current Opinion in Hematology, 1994, 1, 69-77.	1.2	34
401	A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution. Frontiers in Immunology, 2020, 11, 631319.	2.2	33
402	Inhibition of human natural killer cell activity by (14R,15S)-14,15-dihydroxy-5Z,8Z,10E,12E-icosatetraenoic acid.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 6914-6918.	3.3	32
403	Characterization of lipoxins by combined gas chromatography and electron-capture negative ion chemical ionization mass spectrometry: Formation of lipoxin A4 by stimulated human whole blood. Biological Mass Spectrometry, 1991, 20, 45-52.	0.5	32
404	Novel Antiinflammatory Targets for Asthma. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 658-661.	1.4	32
405	Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators. Clinical Chemistry and Laboratory Medicine, 1999, 37, 299-309.	1.4	31
406	Lipid Mediator Informatics and Proteomics in Inflammation-Resolution. Scientific World Journal, The, 2006, 6, 589-614.	0.8	31
407	Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating TÂcell responses and modifies the spinal cord lipidome. Cell Reports, 2021, 35, 109201.	2.9	30
408	E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Seminars in Immunology, 2022, 59, 101597.	2.7	30
409	Novel polyisoprenyl phosphates block phospholipase D and human neutrophil activation in vitro and murine peritoneal inflammation in vivo. British Journal of Pharmacology, 2005, 146, 344-351.	2.7	29
410	Synthesis of 13(R)-Hydroxy-7Z,10Z,13R,14E,16Z,19Z Docosapentaenoic Acid (13R-HDPA) and Its Biosynthetic Conversion to the 13-Series Resolvins. Journal of Natural Products, 2016, 79, 2693-2702.	1.5	28
411	Frontline Science: Structural insights into Resolvin D4 actions and further metabolites via a new total organic synthesis and validation. Journal of Leukocyte Biology, 2018, 103, 995-1010.	1.5	28
412	Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. Biochemical and Biophysical Research Communications, 2018, 504, 553-561.	1.0	28
413	Lipoxin A4 Counter-regulates Histamine-stimulated Glycoconjugate Secretion in Conjunctival Goblet Cells. Scientific Reports, 2016, 6, 36124.	1.6	27
414	Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?. Journal of Clinical Investigation, 1997, 99, 1147-1148.	3.9	27

#	Article	IF	Citations
415	Lipid mediator informatics-lipidomics: Novel pathways in mapping resolution. AAPS Journal, 2006, 8, E284-E297.	2.2	26
416	Novel Endogenous Proresolving Molecules:Essential Fatty Acid-Derived and Gaseous Mediators in the Resolution of Inflammation. Journal of Atherosclerosis and Thrombosis, 2016, 23, 655-664.	0.9	26
417	Cell-Cell Interaction in the Transcellular Biosynthesis of Novel Ï‰-3-Derived Lipid Mediators. , 2006, 341, 227-250.		25
418	Resolvin D1 Increases Mucin Secretion in Cultured Rat Conjunctival Goblet Cells via Multiple Signaling Pathways. , 2017, 58, 4530.		25
419	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. Cell Chemical Biology, 2019, 26, 244-254.e4.	2.5	25
420	Vacuolar (H+)-ATPase Critically Regulates Specialized Proresolving Mediator Pathways in Human M2-like Monocyte-Derived Macrophages and Has a Crucial Role in Resolution of Inflammation. Journal of Immunology, 2019, 203, 1031-1043.	0.4	24
421	Renal hemodynamic actions of lipoxins in rats: a comparative physiological study. American Journal of Physiology - Renal Physiology, 1992, 263, F436-F442.	1.3	23
422	Immunoresolvents signaling molecules at intersection between the brain and immune system. Current Opinion in Immunology, 2018, 50, 48-54.	2.4	23
423	Resolvin D1 treatment on goblet cell mucin and immune responses in the chronic allergic eye disease (AED) model. Mucosal Immunology, 2019, 12, 145-153.	2.7	23
424	The need for precision nutrition, genetic variation and resolution in Covid-19 patients. Molecular Aspects of Medicine, 2021, 77, 100943.	2.7	23
425	Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation. Journal of Pharmacology and Experimental Therapeutics, 1998, 285, 252-61.	1.3	23
426	Aspirin-Triggered 15-Epi-Lipoxin A4 and Novel Lipoxin B4 Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability. Advances in Experimental Medicine and Biology, 1999, 469, 287-293.	0.8	22
427	Identification of endogenous resolvin E1 and other lipid mediators derived from eicosapentaenoic acid via electrospray low-energy tandem mass spectrometry: spectra and fragmentation mechanisms. Rapid Communications in Mass Spectrometry, 2007, 21, 7-22.	0.7	21
428	Addition of aspirin to a fish oil-rich diet decreases inflammation and atherosclerosis in ApoE-null mice. Journal of Nutritional Biochemistry, 2016, 35, 58-65.	1.9	21
429	Protectins PCTR1 and PD1 Reduce Viral Load and Lung Inflammation During Respiratory Syncytial Virus Infection in Mice. Frontiers in Immunology, 2021, 12, 704427.	2.2	21
430	Plasma lipoxin A₄ and resolvin D1 are not associated with reduced adenoma risk in a randomized trial of aspirin to prevent colon adenomas. Molecular Carcinogenesis, 2017, 56, 1977-1983.	1.3	20
431	Biosynthetic metabolomes of cysteinylâ€containing immunoresolvents. FASEB Journal, 2019, 33, 13794-13807.	0.2	20
432	Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1_{nâ”3â€‰DPA}. Chemistry - A European Journal, 2019, 25, 1476-1480.	1.7	20

#	Article	IF	Citations
433	Appearance of an arachidonic acid 15-lipoxygenase pathway upon differentiation of the human promyelocytic cell-line HL-60. FEBS Letters, 1985, 185, 14-18.	1.3	19
434	Carrier-mediated transport of lipoxin A4 in human neutrophils. American Journal of Physiology - Cell Physiology, 1994, 267, C1525-C1534.	2.1	19
435	Potential vascular roles for lipoxins in the â€œstop programsâ€•of host defense and inflammation. Trends in Cardiovascular Medicine, 1995, 5, 186-192.	2.3	19
436	Preventing injury from within, using selective cPLA2 inhibitors. Nature Immunology, 2000, 1, 13-15.	7.0	19
437	Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases?. Expert Opinion on Therapeutic Targets, 2004, 8, 643-652.	1.5	19
438	Induction of functional lipoxin A4 receptors in HL-60 cells. Blood, 1993, 81, 3395-403.	0.6	19
439	Specialized Proresolving Mediators Rescue Infant Mice from Lethal Citrobacter rodentium Infection and Promote Immunity against Reinfection. Infection and Immunity, 2017, 85, .	1.0	18
440	Cysteinyl-specialized proresolving mediators link resolution of infectious inflammation and tissue regeneration via TRAF3 activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
441	Lipoxins, Aspirin-Triggered 15-epi-Lipoxin Stable Analogs and Their Receptors in Anti-Inflammation: A Window for Therapeutic Opportunity. , 2000, , 143-185.		18
442	Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. Infection and Immunity, 2018, 86, .	1.0	16
443	15-Hydroxyeicosatetraenoic Acid Inhibits Superoxide Anion Generation by Human Neutrophils: Relationship to Lipoxin Production. Free Radical Research Communications, 1989, 7, 341-345.	1.8	15
444	New mechanism for an old drug Aspirin triggers anti-inflammatory lipid mediators with gender implications. Comprehensive Therapy, 2006, 32, 150-157.	0.2	15
445	Synthesis of protectin D1 analogs: novel pro-resolution and radiotracer agents. Organic and Biomolecular Chemistry, 2018, 16, 6818-6823.	1.5	15
446	Resolvin D2 elevates cAMP to increase intracellular [Ca ²⁺] and stimulate secretion from conjunctival goblet cells. FASEB Journal, 2019, 33, 8468-8478.	0.2	15
447	Stereoselective Synthesis and Structural Confirmation of the Specialized Pro-Resolving Mediator Resolvin E4. Journal of Organic Chemistry, 2021, 86, 3535-3545.	1.7	15
448	Lipoxins and Aspirin-Triggered Lipoxins in Airway Responses. Advances in Experimental Medicine and Biology, 2003, 525, 19-23.	0.8	15
449	Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. Advances in Experimental Medicine and Biology, 2019, 1161, 13-25.	0.8	15
450	Polyisoprenyl phosphates: natural antiinflammatory lipid signals. Cellular and Molecular Life Sciences, 2002, 59, 729-741.	2.4	14

#	Article	IF	Citations
451	Is C-Reactive Protein an Inflammation Opsonin That Signals Colon Cancer Risk?. JAMA - Journal of the American Medical Association, 2004, 291, 623.	3.8	14
452	Fish Oil Supplementation in Pregnancy. New England Journal of Medicine, 2016, 375, 2599-2601.	13.9	14
453	Signaling pathways activated by resolvin E1 to stimulate mucin secretion and increase intracellular Ca 2+ in cultured rat conjunctival goblet cells. Experimental Eye Research, 2018, 173, 64-72.	1.2	14
454	Lipid Mediator Informatics-Lipidomics: Novel Pathways in Mapping Resolution. AAPS Journal, 2006, 08, E284.	2.2	14
455	Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Archivum Immunologiae Et Therapiae Experimentalis, 2001, 49, 177-88.	1.0	14
456	Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug. Discovery Medicine, 2004, 4, 470-5.	0.5	14
457	Human leukocytes selectively convert 4 S ,5 S -epoxy-resolvin to resolvin D3, resolvin D4, and a cys-resolvin isomer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
458	[20] High-performance liquid chromatography separation and determination of lipoxins. Methods in Enzymology, 1990, 187, 167-175.	0.4	13
459	Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5. Science Advances, 2019, 5, eaax0629.	4.7	13
460	Dâ€series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution. FASEB Journal, 2020, 34, 15888-15906.	0.2	13
461	Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity. FASEB Journal, 2020, 34, 10560-10573.	0.2	13
462	NPD1 rapidly targets mitochondria-mediated apoptosis after acute injection protecting brain against ischemic injury. Experimental Neurology, 2021, 335, 113495.	2.0	13
463	RvE1 uses the LTB4 receptor BLT1 to increase [Ca2+]i and stimulate mucin secretion in cultured rat and human conjunctival goblet cells. Ocular Surface, 2020, 18, 470-482.	2.2	12
464	Pro-Resolving Mediator Annexin A1 Regulates Intracellular Ca2+ and Mucin Secretion in Cultured Goblet Cells Suggesting a New Use in Inflammatory Conjunctival Diseases. Frontiers in Immunology, 2021, 12, 618653.	2.2	12
465	Local and Systemic Delivery of an Aspirinâ€Triggered Lipoxin Stable Analog Inhibits Neutrophil Trafficking. Annals of the New York Academy of Sciences, 2000, 905, 274-278.	1.8	11
466	Resolvins and protectins: novel lipid mediators in anti-inflammation and resolution. Food Nutrition Research, 2006, 50, 68-78.	0.3	11
467	Acute and Chronic Inflammation. , 0, , 1-16.		11
468	Interactions Between Lipoxin A4, the Stable Analogue 16-phenoxy-lipoxin A4 and Leukotriene B4 in Cytokine Generation by Human Monocytes. Scandinavian Journal of Immunology, 2004, 60, 249-256.	1.3	10

#	Article	IF	Citations
469	Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins. , 2010, , 153-174.		10
470	Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys. American Journal of Pathology, 2019, 189, 1953-1972.	1.9	10
471	Resolvin D1, but not resolvin E1, transactivates the epidermal growth factor receptor to increase intracellular calcium and glycoconjugate secretion in rat and human conjunctival goblet cells. Experimental Eye Research, 2019, 180, 53-62.	1.2	10
472	Resolvin E1 Reduces Leukotriene B4â€“Induced Intracellular Calcium Increase and Mucin Secretion in Rat Conjunctival Goblet Cells. American Journal of Pathology, 2020, 190, 1823-1832.	1.9	10
473	Maresin 1, a specialized proresolving mediator, stimulates intracellular [Ca²⁺] and secretion in conjunctival goblet cells. Journal of Cellular Physiology, 2021, 236, 340-353.	2.0	10
474	Bang and Dyerbergâ€™s omega-3 discovery turns fifty. Nature Food, 2021, 2, 303-305.	6.2	10
475	PCTR1 Enhances Repair and Bacterial Clearance in Skin Wounds. American Journal of Pathology, 2021, 191, 1049-1063.	1.9	10
476	Polyisoprenyl Phosphate Signaling: Topography in Human Neutrophils. Biochemical and Biophysical Research Communications, 2000, 275, 739-745.	1.0	9
477	A new synthetic protectin D1 analog 3-oxa-PD1_{n-3 DPA} reduces neuropathic pain and chronic itch in mice. Organic and Biomolecular Chemistry, 2021, 19, 2744-2752.	1.5	9
478	Specialized proâ€resolving mediators: wiring the circuitry of effector immune and tissue homeostasis. Endodontic Topics, 2011, 24, 39-58.	0.5	8
479	Staphylococcus aureus controls eicosanoid and specialized proâ€resolving mediator production via lipoteichoic acid. Immunology, 2022, 166, 47-67.	2.0	8
480	Formation of leukotriene C4by human leukocytes exposed to monosodium urate crystals. FEBS Letters, 1984, 167, 109-112.	1.3	7
481	Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brainâœ°. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 162, 102176.	1.0	7
482	Periodontal Stem Cells Synthesize Maresin Conjugate in Tissue Regeneration 3. Journal of Dental Research, 2022, , 002203452210908.	2.5	7
483	Clues for New Therapeutics in Osteoporosis. New England Journal of Medicine, 2004, 350, 1902-1903.	13.9	6
484	A newly synthesized 17-epi-NeuroProtectin D1/17-epi-Protectin D1: Authentication and functional regulation of Inflammation-Resolution. Biochemical Pharmacology, 2022, 203, 115181.	2.0	6
485	Leukocyte transmigration, chemotaxis, and oxygenated derivatives of arachidonic acid: when is chirality important?. American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 251-253.	1.4	5
486	Lipid Signatures of Unstable Atheromas. Circulation: Cardiovascular Genetics, 2011, 4, 215-217.	5.1	5

#	Article	IF	Citations
487	Selective identification of specialized pro-resolving lipid mediators from their biosynthetic double di-oxygenation isomers. RSC Advances, 2016, 6, 28820-28829.	1.7	5
488	Stereoselective synthesis of MaR2n-3 DPA. Tetrahedron Letters, 2020, 61, 151510.	0.7	5
489	Sex Hormoneâ€“Dependent Lipid Mediator Formation in Male and Female Mice During Peritonitis. Frontiers in Pharmacology, 2021, 12, 818544.	1.6	5
490	COVID-19 and cancer: start the resolution!. Cancer and Metastasis Reviews, 2022, 41, 1-15.	2.7	5
491	Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking. Thorax, 2000, 55, 10S-12.	2.7	4
492	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2006, , 672271.	0.2	4
493	Models of Acute Inflammation â€“ Air-Pouch, Peritonitis, and Ischemia-Reperfusion. , 0, , 329-337.		4
494	Moving Beyond â€œGood Fat, Bad Fatâ€: The Complex Roles of Dietary Lipids in Cellular Function and Health. Advances in Nutrition, 2012, 3, 60-68.	2.9	4
495	Proâ€Resolving Lipid Mediators and Antiâ€Angiogenic Therapy Exhibit Synergistic Antiâ€Tumor Activity via Resolvin Receptor Activation. FASEB Journal, 2020, 34, 1-1.	0.2	4
496	Lipoxin formation: evaluation of the role and actions of leukotriene A4. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1990, 20, 54-62.	0.2	4
497	First stereoselective total synthesis of 4(S),5(S)-oxido-17(S)-hydroxy-6(E),8(E),10(Z),13(Z),15(E),19(Z)-docosa acid, the biosynthetic precursor of resolvins D3 and D4. RSC Advances, 2022, 12, 11613-11618.	1.9	4
498	Signaling Pathways Used by the Specialized Pro-Resolving Mediator Maresin 2 Regulate Goblet Cell Function: Comparison with Maresin 1. International Journal of Molecular Sciences, 2022, 23, 6233.	1.8	4
499	Human Red Cells Enhance the Formation of 5-Lipoxygenase-Derived Products by Neutrophils. Free Radical Research Communications, 1989, 7, 335-339.	1.8	3
500	Macrophages and the Entrance of Resolution Phase Lipid Mediators. , 2014, , 287-314.		3
501	Update on Arachidonic Acid Cascade. , 1999, , 51-92.		3
502	Lipoxin recognition sites of human neutrophils. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1994, 22, 317-26.	0.2	3
503	Resolvin D2 and Resolvin D1 Differentially Activate Protein Kinases to Counter-Regulate Histamine-Induced [Ca2+]i Increase and Mucin Secretion in Conjunctival Goblet Cells. International Journal of Molecular Sciences, 2022, 23, 141.	1.8	3
504	The discovery and characterization of the leukotrienes. Journal of Allergy and Clinical Immunology, 2006, 118, 972-976.	1.5	2

#	Article	IF	Citations
505	A Novel Polyisoprenyl Phosphate Signaling Cascade in Human Neutrophils. Annals of the New York Academy of Sciences, 2000, 905, 69-80.	1.8	2
506	Novel lipid mediators in resolution and their aspirin triggered epimers: Lipoxins, resolvins, and protectins. , 2008, , 93-117.		2
507	Resolution of Acute Inflammation and Wound Healing. , 2010, , 17-27.		2
508	Cytokines and Chemokines in Inflammation. , 0, , 175-185.		2
509	Animal Models of Rheumatoid Arthritis. , 0, , 385-412.		2
510	Links between Innate and Adaptive Immunity. , 0, , 28-38.		2
511	Fibroblasts and Stromal Cells. , 0, , 126-140.		2
512	Endogenous Anti-inflammatory and Proresolving Lipid Mediators in Renal Disease. , 2011, , 69-92.		2
513	P1-099: ALTERED LIPID MEDIATORS AND RECEPTORS OF RESOLUTION IN THE ENTORHINAL CORTEX OF ALZHEIMER'S DISEASE. , 2014, 10, P338-P338.		2
514	Neuroprotectin <scp>D1</scp> Attenuates Blast Overpressure Induced Reactive Microglial Cells in the Cochlea. Laryngoscope, 2021, 131, E2018-E2025.	1.1	2
515	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
516	Selective incorporation of 15-HETE in phosphatidylinositol: agonist-induced deacylation and transformation of stored HETEs by human neutrophils. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1991, 21A, 105-8.	0.2	2
517	Polyisoprenyl phosphates: a novel class of intracellular stop signals in neutrophils. Expert Opinion on Therapeutic Targets, 1998, 2, 27-29.	1.0	1
518	Neutrophilâ€“Endothelial Cell Interactions. , 0, , 141-152.		1
519	A Novel Genus of Specialized Anti-Inflammatory and Pro-Resolution Lipid Mediators. NeuroImmune Biology, 2010, 9, 37-57.	0.2	1
520	Cytokines and Chemokines in Inflammation and Cancer. , 0, , 244-252.		1
521	Ocular Inflammation Models. , 0, , 413-426.		1
522	Neutrophils II. , 0, , 49-64.		1

#	Article	IF	Citations
523	Lymphocytes. , 0, , 107-125.		1
524	Formylpeptide receptors in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	1
525	Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins and Other Lipid Mediators, 2004, 73, 155-172.	1.0	1
526	Lipoxins and Aspirin-Triggered 15-epi-Lipoxins: Mediators in Anti-inflammation and Resolution. , 2003, , 281-285.		1
527	Synergy between Resolvins and Immune Checkpoint Blockade in a Novel Transplantable FANCC â˜'/â˜' Murine Head and Neck Tumor Model. FASEB Journal, 2019, 33, 496.10.	0.2	1
528	Leukocyte Generation of Reactive Oxygen Species. , 0, , 198-207.		0
529	Nonsteroidal Anti-Inflammatory Drugs. , 0, , 234-243.		0
530	Oral Inflammation and Periodontitis. , 0, , 433-447.		0
531	Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases. , 0, , 186-197.		0
532	Neural Inflammation, Alzheimer's Disease, and Stroke. , 0, , 259-266.		0
533	Rheumatoid Arthritis/SLE. , 0, , 267-281.		0
534	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0, , 282-298.		0
535	Inflammation in Cardiovascular Diseases. , 0, , 317-328.		0
536	Glomerulonephritis and Ischemia Reperfusion Injury. , 0, , 349-375.		0
537	Atherosclerosis in Experimental Animal Models. , 0, , 427-432.		0
538	Pathogens and Inflammation. , 0, , 448-456.		0
539	Mediators and Mechanisms of Inflammatory Pain. , 0, , 217-233.		0
540	Inflammatory Skin Diseases. , 0, , 299-303.		0

#	Article	IF	Citations
541	Cell Adhesion Molecules. , 0, , 208-216.		0
542	Kidney Glomerulonephritis and Renal Ischemia. , 0, , 304-316.		0
543	Neutrophils I. , 0, , 39-48.		0
544	Mast Cells as Sentinels of Inflammation. , 0, , 65-73.		0
545	Basophils. , 0, , 74-85.		0
546	Eosinophils. , 0, , 86-95.		0
547	Macrophages. , 0, , 96-106.		0
548	Lipoxins and Aspirin-Triggered 15-epi-Lipoxins. , 2010, , 1235-1242.		0
549	Lung. , 0, , 253-258.		0
550	Experimental Models of Glomerulonephritis. , 0, , 338-348.		0
551	CHARLES N. SERHAN, PHD, The Simon Gelman Professor of Anaesthesia, Director, Center for Experimental Therapeutics & Reperfusion Injury, Professor, Department of Oral Medicine, Infection & Immunity, Department of Biochemistry & Molecular Pharmacology, Harv. Endodontic Topics, 2011, 24, 153-153.	0.5	0
552	Roles of Specialized Proresolving Lipid Mediators in Inflammation Resolution and Tissue Repair. , 0, , 1447-1466.		0
553	Nutrients and Gene Expression in Inflammation. , 2020, , 457-467.		0
554	Lipoxins and resolvins: Local mediators in endogenous anti-inflammation and resolution. , 2004, , 169-210.		0
555	Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB Journal, 2007, 21, A131.	0.2	0
556	Aspirinâ€triggered lipoxins override the apoptosisâ€delaying action of myeloperoxidase in human neutrophils. FASEB Journal, 2009, 23, 739.3.	0.2	0
557	Temporal Regulation of Proâ€Resolving Mediators and MicroRNA in Selfâ€Limited versus Delayed Resolution of Acute Inflammation. FASEB Journal, 2013, 27, 816.4.	0.2	0
558	Resolvin D1 Receptor Activation Counterâ€regulates H1 histamine receptors in human and rat conjunctival goblet cells. FASEB Journal, 2013, 27, 132.6.	0.2	0

#	Article	IF	Citations
559	Inhaled Carbon Monoxide Accelerates Resolution of Inflammation via Novel Proâ€resolving Mediators and Heme Oxygenaseâ€1. FASEB Journal, 2013, 27, 649.2.	0.2	0
560	Resolvin D1 and Resolvin D5 Lower Antibiotic Doses in Infection. FASEB Journal, 2013, 27, 138.9.	0.2	0
561	Novel Anti-Inflammatory and Proresolution Lipid Mediators in Induction and Modulation of Phagocyte Function. , 0, , 265-280.		0
562	Formylpeptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
563	A tribute to Gerald Weissmann (1930â€“2019). Journal of Clinical Investigation, 2019, 129, 4553-4555.	3.9	0
564	Leukotriene receptors (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
565	On the generation of lipoxins and novel related compounds by human neutrophils: relationship to leukotriene production. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1989, 19, 116-21.	0.2	0